Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | CASP1 | P29466 | 1/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.36 |
| ▸ | CNR2 | P34972 | 2/20 | 0.35 |
| ▸ | SUV39H2 | Q9H5I1 | 10/20 | 0.34 |
| ▸ | CNR1 | P21554 | 1/20 | 0.34 |
| ▸ | MAOB | P27338 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | DRD2 | P14416 | 2/20 | 0.33 |
| ▸ | DRD3 | P35462 | 2/20 | 0.33 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16782257 | 0.97 | NPC1 (0.43) | NPC1ALDH1A1RAB9AKDM4EL3MBTL1 | |
| SCHEMBL16782248 | 0.90 | ALDH1A1 (0.40) | NPC1ALDH1A1RAB9AKDM4EL3MBTL1 | |
| SCHEMBL15230839 | 0.89 | NPC1 (0.42) | NPC1ALDH1A1RAB9AKDM4EL3MBTL1 | |
| SCHEMBL16782185 | 0.87 | ALDH1A1 (0.45) | NPC1ALDH1A1RAB9AKDM4EL3MBTL1 | |
| SCHEMBL16782254 | 0.86 | ALDH1A1 (0.43) | NPC1ALDH1A1RAB9AKDM4EL3MBTL1 | |
| SCHEMBL15243891 | 0.85 | ALDH1A1 (0.49) | NPC1ALDH1A1RAB9AKDM4EL3MBTL1 | |
| SCHEMBL15243886 | 0.85 | HRH3 (0.35) | NPC1ALDH1A1RAB9AKDM4EL3MBTL1 | |
| SCHEMBL16782192 | 0.84 | KDM4E (0.50) | NPC1ALDH1A1RAB9AKDM4EL3MBTL1 | |
| SCHEMBL15231098 | 0.84 | ALDH1A1 (0.42) | NPC1ALDH1A1RAB9AKDM4EL3MBTL1 | |
| SCHEMBL21515360 | 0.84 | NPC1 (0.39) | NPC1ALDH1A1RAB9AKDM4EL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2819519-B1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | PTC THERAPEUTICS INC (US) | 2019-10-23 | — | — | EP | claimed |
| US-9371336-B2 | Compounds for treating spinal muscular atrophy | PTC THERAPEUTICS, INC. (US) | 2016-06-21 | — | — | US | claimed |
| US-20150166575-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | PTC THERAPEUTICS INC. (US) | 2015-06-18 | — | — | US | claimed |
| EP-2819519-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | PTC Therapeutics, Inc. (US) | 2015-01-07 | — | — | EP | claimed |
| WO-2013130689-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | PTC THERAPEUTICS, INC. (US) | 2013-09-06 | — | — | WO | claimed |
| EP-2819519-B1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | PTC THERAPEUTICS INC (US) | 2019-10-23 | — | — | EP | disclosed |
| US-9371336-B2 | Compounds for treating spinal muscular atrophy | PTC THERAPEUTICS, INC. (US) | 2016-06-21 | — | — | US | disclosed |
| US-9371336-B2 | Compounds for treating spinal muscular atrophy | PTC THERAPEUTICS, INC. (US) | 2016-06-21 | — | — | US | disclosed |
| US-20150166575-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | PTC THERAPEUTICS INC. (US) | 2015-06-18 | — | — | US | disclosed |
| US-20150166575-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | PTC THERAPEUTICS INC. (US) | 2015-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150166575-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | SMN1; SMN2, CPT1B, GYS1 | NPC1 975/4885ALDH1A1 1461/4885RAB9A 1728/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.